海正药业
(600267)
| 流通市值：138.94亿 | | | 总市值：138.94亿 |
| 流通股本：11.99亿 | | | 总股本：11.99亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,390,467,858.12 | 10,549,640,956.88 | 7,922,794,186.82 | 5,250,334,553.43 |
| 营业收入 | 2,390,467,858.12 | 10,549,640,956.88 | 7,922,794,186.82 | 5,250,334,553.43 |
| 二、营业总成本 | 2,063,639,937.5 | 9,450,690,106.08 | 7,073,625,021.67 | 4,675,003,997.9 |
| 营业成本 | 1,174,489,303.32 | 5,819,865,024.29 | 4,358,649,302.4 | 2,943,459,569.95 |
| 税金及附加 | 33,028,244.9 | 117,265,693.11 | 83,988,165.73 | 52,043,017.2 |
| 销售费用 | 521,646,476.91 | 2,078,460,063.73 | 1,609,805,985.09 | 1,063,975,689.75 |
| 管理费用 | 184,807,282.73 | 872,523,571.04 | 587,921,517.94 | 373,562,587.03 |
| 研发费用 | 134,437,997.58 | 478,539,580.32 | 372,154,095.37 | 202,367,069.77 |
| 财务费用 | 15,230,632.06 | 84,036,173.59 | 61,105,955.14 | 39,596,064.2 |
| 其中:利息费用 | 16,722,345.83 | 100,076,115.64 | 78,464,830.99 | 54,716,456.28 |
| 其中:利息收入 | 4,114,299.69 | 20,854,594.46 | 17,064,722.46 | 14,268,500.13 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -378,922.12 | -34,782,686.47 | -36,370,692.67 | -35,878,704.73 |
| 加:投资收益 | 175,229,670.88 | -36,697,762.95 | -34,534,648.03 | -33,045,798.2 |
| 资产处置收益 | 1,046,511.6 | 5,234,365.98 | 2,340,902.89 | 305,012.36 |
| 资产减值损失(新) | -48,010,158.66 | -213,171,765.88 | -162,306,635.28 | -99,263,012.41 |
| 信用减值损失(新) | 7,881,191.13 | -50,563,585.41 | -44,600,711.67 | -43,199,375.12 |
| 其他收益 | 20,933,854.23 | 98,066,656.91 | 69,026,284.75 | 55,210,250.62 |
| 四、营业利润 | 483,530,067.68 | 867,036,072.98 | 642,723,665.14 | 419,458,928.05 |
| 加:营业外收入 | 475,293.27 | 8,337,490.04 | 7,572,600.25 | 6,742,125 |
| 减:营业外支出 | 1,545,328.07 | 59,997,450 | 30,561,126.79 | 21,900,871.41 |
| 五、利润总额 | 482,460,032.88 | 815,376,113.02 | 619,735,138.6 | 404,300,181.64 |
| 减:所得税费用 | 123,912,957.9 | 267,890,410.59 | 151,677,328.5 | 99,386,552.1 |
| 六、净利润 | 358,547,074.98 | 547,485,702.43 | 468,057,810.1 | 304,913,629.54 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 358,547,074.98 | 547,485,702.43 | 468,057,810.1 | 304,913,629.54 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 355,690,873.08 | 540,707,781.22 | 460,929,192.8 | 299,070,584.84 |
| 少数股东损益 | 2,856,201.9 | 6,777,921.21 | 7,128,617.3 | 5,843,044.7 |
| 扣除非经常损益后的净利润 | 235,775,846.48 | 585,676,238.11 | 490,513,193.75 | 321,225,615.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.31 | 0.46 | 0.4 | 0.26 |
| (二)稀释每股收益 | 0.31 | 0.46 | 0.4 | 0.26 |
| 八、其他综合收益 | -1,575,109.08 | -2,385,203.76 | -1,325,403.18 | -605,808.91 |
| 归属于母公司股东的其他综合收益 | -1,575,109.08 | -2,385,203.76 | -1,325,403.18 | -605,808.91 |
| 九、综合收益总额 | 356,971,965.9 | 545,100,498.67 | 466,732,406.92 | 304,307,820.63 |
| 归属于母公司股东的综合收益总额 | 354,115,764 | 538,322,577.46 | 459,603,789.62 | 298,464,775.93 |
| 归属于少数股东的综合收益总额 | 2,856,201.9 | 6,777,921.21 | 7,128,617.3 | 5,843,044.7 |
| 公告日期 | 2026-04-28 | 2026-04-08 | 2025-10-28 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |